Vaxxinity, Inc. (VAXX)
USD 0.05
(200.0%)
USD 0.05
(200.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -2.23 Million USD | -32.66% |
| 2022 | -1.68 Million USD | 9.99% |
| 2021 | -1.87 Million USD | -470.5% |
| 2020 | 505 Thousand USD | 571.96% |
| 2019 | -107 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q3 | -666 Thousand USD | -30.08% |
| 2023 Q2 | -512 Thousand USD | 14.67% |
| 2023 Q1 | -600 Thousand USD | -11.11% |
| 2023 FY | -2.23 Million USD | -32.66% |
| 2023 Q4 | -456 Thousand USD | 31.53% |
| 2022 Q4 | -540 Thousand USD | 0.0% |
| 2022 Q3 | - USD | 100.0% |
| 2022 Q2 | -392 Thousand USD | -17.72% |
| 2022 Q1 | -333 Thousand USD | -90.29% |
| 2022 FY | -1.68 Million USD | 9.99% |
| 2021 Q4 | -175 Thousand USD | -526.83% |
| 2021 Q3 | 41 Thousand USD | 102.13% |
| 2021 Q2 | -1.92 Million USD | -12143.75% |
| 2021 FY | -1.87 Million USD | -470.5% |
| 2021 Q1 | 16 Thousand USD | 0.0% |
| 2020 Q2 | 211 Thousand USD | 0.0% |
| 2020 FY | 505 Thousand USD | 571.96% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q4 | - USD | 100.0% |
| 2020 Q3 | -61 Thousand USD | -128.91% |
| 2019 FY | -107 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| America Great Health | 168.58 Thousand USD | 1425.124% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -793.6% |
| Aridis Pharmaceuticals, Inc. | - USD | Infinity% |
| Biora Therapeutics, Inc. | -551 Thousand USD | -305.445% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | -1155.056% |
| Better Therapeutics, Inc. | -2.72 Million USD | 18.139% |
| Calithera Biosciences, Inc. | -1.38 Million USD | -61.3% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 628.492% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 90.253% |
| Eloxx Pharmaceuticals, Inc. | - USD | Infinity% |
| Evelo Biosciences, Inc. | - USD | Infinity% |
| Evolutionary Genomics, Inc. | -1.02 Million USD | -118.699% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 68.5% |
| Galera Therapeutics, Inc. | -259 Thousand USD | -762.548% |
| Innovation1 Biotech Inc. | -52.69 Thousand USD | -4139.25% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 20.097% |
| Molecular Templates, Inc. | 50.39 Million USD | 104.433% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -1772.669% |
| NexImmune, Inc. | -1.02 Million USD | -117.957% |
| Orgenesis Inc. | -5.72 Million USD | 60.978% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 91.289% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | -48454.662% |
| PaxMedica, Inc. Common Stock | - USD | Infinity% |
| Scopus BioPharma Inc. | - USD | Infinity% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 107.602% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | -357.493% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | -862.931% |
| Trevena, Inc. | 1.45 Million USD | 253.54% |
| Vaccinex, Inc. | -16 Million USD | 86.041% |
| Vicapsys Life Sciences, Inc. | - USD | Infinity% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | -354.065% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | 19342.033% |